The current situation of sleeping sickness in Tanzania, especially the outbreak in Kigoma region, is caused by the following factors: Poor surveillance due to inadequate funding and staff. Inadequate and erratic supply of specific trypanocidal drugs. Poorly equipped field laboratories for diagnosis.

27, 62-64; WHO-TDR PR-6 83.2-MAL, item 2.15, p. 25 ; have indicated that continued pursuit of these investigations would benefit from access to hitherto unpublished results of the aforementioned studies on the activities of CGT-P alone and in combination with DADDS against infections with both drug-susceptible and pyrimethamine-resistant strains of P. cynomolgi. This report is concerned with the conduct, results, and implications of the major and as yet unpublished segments of these investigations. MATERIALS AND METHODS Since many of the technical procedures used in the series of experiments recorded in this report were tailored to the objectives of individual studies, it has seemed best to detail these special methods along with the results of the experiments that they served. Only the more generally used materials and methods will be described in this section. Test compounds, preparations for use, and methods of administration. Four lots of CGT-P 8652, 4699-X74, 9163, and 590647 ; , one lot of DADDS 9029 ; , and one lot of CGT hydrochloride 4460X16 ; , all provided by Paul Thompson, Research Division, Parke, Davis & Co., were used in the studies included in this report. The lots of CGT-P differed from each other with respect to particle size. Lot 8652, with particles ranging from 1 to 105 , u in greatest dimensions, with 70% in excess of 50 , u, was categorized as a large-sized particle preparation. Lots 4699-X74, 9163, and 590647, with respective particle sizes of 10 to 40, 10 to 50, and 25 to 50 pL, were categorized as medium-sized particle preparations. The single lot of DADDS, made up of particles averaging 36 , u in greatest dimensions, was prepared'to match the mediumsized particle lots of CGT-P. Lot 8652 of CGT-P, the first and most frequently used preparation in our studies, was provided in 5-ml glass vials as a sterile suspension with the equivalent of 150 mg of CGT base per ml in a 40% benzyl benzoate-60% castor oil vehicle. Lots 4699-X74, 9163, and 590647 of CGT-P were provided as bulk crystalline powders, as were DADDS and CGT hydrochloride. The quantity of such a bulk preparation approximately 20% larger than that required for dosing all monkeys in a specific experiment was autoclaved in a sealed vial, under conditions that assured maintenance of chemical integrity 60 ; , and then transferred to an Erlenmeyer flask with a Teflon-lined screw cap and suspended by intensive shaking in either sterile benzyl benzoate-castor oil or aqueous vehicle. The latter, also provided by Thompson, was a proprietary mixture of dispersing agents with polysaccharides to impart viscosity and was used only with lot 4699-X74 of CGT-P. Stock suspensions of CGT-P containing the equivalent of 150 mg of CGT per ml met the largest dos'e needs of all experiments in which this compound was administered alone. Suspensions containing 300 mg of CGT per ml were required when this agent was administered in combination with DADDS. Stock suspensions of DADDS containing the equivalent of 300 mg of dapsone per ml were required in some studies involving both single and combination agent regimens. Stock suspensions of CGT-P plus DADDS were prepared by blending the appropriate volumes of the stock suspensions of the individual agents. Irrespective of dose, suspensions of CGT-P alone, DADDS alone, or combinations of these agents were administered in a volume of 0.5 ml kg of body weight. This volume was achieved by diluting the appropriate amounts of the stock suspensions with either the oleaginous or the aqueous vehicle. CGT-P, DADDS, and their combinations were injected into the gluteal muscle mass of the flexed right thigh.

Immediately, if the LNG-IUD is inserted within 7 days after first- or second-trimester abortion or miscarriage and if no infection is present. No need for a backup method. If it is more than 7 days after first- or secondtrimester miscarriage or abortion and no infection is present, she can have the LNG-IUD inserted any time it is reasonably certain she is not pregnant. She will need a backup method for the first 7 days after insertion. If infection is present, treat or refer and help the client choose another method. If she still wants the LNG-IUD, it can be inserted after the infection has completely cleared. LNG-IUD insertion after second-trimester abortion or miscarriage requires specific training. If not specifically trained, delay insertion until at least 4 weeks after miscarriage or abortion.

Microwave oven, model MT6120XBB Q, 900W ; with a subsequent consecutive 1 hour hybridization at 37oC for the first round. The second round consisted of a 5 minute only microwave hybridization at 10% high power. A tray containing 1L pre-warmed water was placed in the microwave under the slide rack to insure even distribution of the microwaves see Fig1 ; . Two standard post-hybridization washes were used in both protocols: wash #1, 0.4xSSC 0.3% Igepol, 2min at 72oC; wash # 2, 2xSSC 0.1% Igepol, 1min at 22oC. Slides were washed between rounds in 0.4xSSC at 72oC for 4 min to remove previous probes. The comparison of probe strength between the two protocols, as well as, the efficiency of probe detection was assessed by random screening of 30 nuclei on each slide using the imaging analysis system of Applied Imaging Santa Clara, CA. [21] 2, 361, 278 [13] A1 [51] Int.Cl. 7C07D 417 06 00 7C07D 313 00 7A61P 35 00 7C07D 493 04 [25] EN [54] 16-HALOGEN-EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING THEM AND THEIR PHARMACEUTICAL USE [54] DERIVES DE 16-HALOGENOEPOTHILON, LEUR PROCEDE DE PRODUCTION ET LEUR UTILISATION PHARMACEUTIQUE [72] SCHWEDE, WOLFGANG, DE [72] BUCHMANN, BERND, DE [72] SCHIRNER, MICHAEL, DE [72] SKUBALLA, WERNER, DE [72] KLAR, ULRICH, DE [71] SCHERING AKTIENGESELLSCHAFT, DE [85] 2001-07-25 [86] 2000-02-18 PCT EP00 01333 ; [87] 2000-08-24 WO00 49021 ; [30] DE 199 08 765.2 ; 1999-02-18 [30] DE 199 54 230.9 ; 1999-11-04 and daptomycin.

F I did-State Device Phenomena It 31C Measurement and Grain-Boundary Recombination in SO1 Polycrystalline Silicon . K.-C. ; Vu, R. W. Dutron, and N . M Johnson 1 ' . Quantitative Model for the Conduction in Oxides Thermally Grown from Polycrystalline Silicon . , Groeseneken and H . E Maes . ltlillimeter-Wave Responses of : I Micro-Contact Josephson Junction Using a New Structure Yoshimori, K. Fukuhara, M . Kawamura and 11, New Driver Circuit for Chip-to-Chip Signal Transmission in Josephson Packaging Taroh, K. Aoki, and H. Yoshikiyo 7l1e Use of Charge Pumping to Characterize Generation by Interface Traps . , . . R.A. Wachnik.

Discussion: The DMERC Medical Directors are on track working on local policy for mobility. They will need to have a draft policy out for comment by mid-May in order to meet the timing requirements for January 2006 implementation. They are working on general issues until CMS has issued the final NCD. Unless NCD is delayed, providers should expect a draft around mid-May for comments. New project The editors of HME news have requested consideration for a medical director Q & A column for their magazine. CMS has agreed. The medical directors will choose the question to answer the response will be a collaboration of all four medical directors. Look for the first Q & A in the May issue. Dr. Hughes is open to receiving questions from the provider community. Providers should send questions to their respective State Association. Projects for summer 17 policies have to be converted to new format. Half will be done in July, the other half in September. They have received comments on the draft knee orthosis policy. This policy has been put on the back burner until the wheelchair policy is completed. Tricenturion has a new CERT documentation contractor. For Region A, for claims on or after January 2005, the new fax number to send information is 240-568-6222. An article will be published soon with more information as well as sample CERT letters. Laraine asked if providers should wait until instructions are received from the DMERC regarding change requests CR ; or can providers start implementing changes in their company based on the change request. Dr. Hughes suggested waiting until the instructions are sent to providers via bulletin or Medlearn articles. An example was given regarding CR3030 which allowed the DMERC to accept supply claims up to 5 days prior to the initial DOS. The DMERC interpreted the CR differently than what it was intended. Any provider who changed their operating procedures based on the change request had their claims denied due to the misunderstanding. Dr. Hughes is looking for topics to discuss at State Association meetings. Providers should send any questions to their respective State Association. Other questions and delavirdine.

Aj a coefficient representing the importance of accessibility to the network for land-use j . It expresses the fact that for some activities, such as industry, a direct access to the road system is more important than for others, such as agriculture. Table below shows the importance of accessibility to the network for each land-use. Table Appendix. iv and demeclocycline.
Imperial Soup Cream Cheese Wontons General Tao's Chicken Kung Pao Beef Hot Burned Pork Szechwan Braised String Beans Steamed Rice Chin's Szechwan Cuisine near Miramar Rd & I-15 ; 9355 Kearny Mesa Road, San Diego Please see Thomas Guide: p.1209, F6 .00 per Dinner .00 with student I.D. No-Shows will be billed and dapsone.
Figure 2: Merged and normalized mass chromatograms with the ions m z 249 and 156 dapsone ; and m z 61 and 298 internal standard ; indicating 18 mg L of dapsone. Table 1: Clinical symptoms in correlation with methemoglobin concentrations in blood according to ref. 18 and desipramine.